Close Menu

Mark Boyle

Dec 21, 2016

Clinical Genomics has appointed Mark Boyle as president of in vitro diagnostics. Boyle joins Clinical Genomics from Qiagen, where he served as a VP for nearly five years. Previously, he served as president of Cellestis, prior to that firm's acquisition by Qiagen and successful integration into the company. He has also served as general manager for the UK subsidiary of Diagnostics Systems Laboratories.

More Like This

Oct 23, 2019

LAM: Alan List

Laboratory for Advanced Medicine has appointed Alan List to its board of directors. A practicing oncologist, List currently serves as president and CEO of the Moffitt Cancer Center in Tampa, Florida. Previously he filled various other roles at Moffitt, including, most recently, executive VP and physician-in-chief. List is an active member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. He earned his medical degree from the University of Pennsylvania.

Oct 23, 2019

Laboratory for Advanced Medicine: Alan List

Laboratory for Advanced Medicine appointed Alan List to the company's board of directors. List is known for his contributions to the development of novel and more effective treatment strategies for several cancer types, the firm said. He serves as president and CEO at Moffitt Cancer Center in Tampa, Florida. Previously, he served as executive vice president and physician-in-chief, vice deputy physician-in-chief, and chief of the malignant hematology division at Moffitt. He is an active member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research.

Oct 23, 2019

Progenity: Sami Shihabi

Progenity promoted Sami Shihabi to chief commercial officer. In his new role, Shihabi will oversee the global commercial operations and corporate development strategies for Progenity’s women’s health and precision medicine business units. He will lead all commercial functional areas including sales, marketing, and managed care. Shihabi joined Progenity in 2018 as senior vice president of marketing and portfolio strategy. He previously was chief commercial officer at Prometheus Laboratories.

Oct 21, 2019

Smith+Nephew: Roland Diggelmann

Smith+Nephew announced Roland Diggelmann will become the company's CEO, effective Nov. 1. He replaces Namal Nawana who is leaving the firm to pursue opportunities outside the UK. Diggelmann has been on Smith+Nephew's board as a non-executive director since March 2018. He spent 11 years at Roche. Before that, he was in strategy and leadership roles at Sulzer Orthopedics and Zimmer, now Zimmer Biomet. 

Oct 21, 2019

Myriad Genetics: Mark Pollack

Myriad Genetics has named Mark Pollack as chief medical officer of Myriad Neuroscience. Pollack will start in this new role on Jan. 15, 2020, and will report to Mark Verratti, president of the neuroscience division. In this position, Pollack will be in charge of efforts to integrate the GeneSight pharmacogenetic test into clinical practice. Pollack is a psychiatrist with three decades of experience in clinical psychiatry and neuroscience. He served as professor and chair of the psychiatry department at Rush University Medical Center in Chicaco, and before that he was a psychiatry professor at Harvard Medical School and directed the Center of Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. 

Oct 17, 2019

Sienna Cancer Diagnostics: Matthew Hoskin, Carl Stubbings

Sienna Cancer Diagnostics announced Matthew Hoskin is stepping down as its CEO. He will be replaced by Carl Stubbings, currently a non-executive director at Sienna. The change is effective immediately. No reason was given for Hoskin's resignation. Stubbings was most recenlty CEO of BCAL, a private company developing a breast cancer diagnostics. 

Oct 16, 2019

Unilabs: Jos Lamers, Michiel Boehmer, and More

Unilabs has appointed Jos Lamers its executive chairman. He is currently the company's CEO. Additionally, Michiel Boehmer, currently Unilabs' regional director south, will become the president and COO of the firm. He will run Unilabs' daily operations, while Lamers will be responsible for its long-term strategy. 

Boehmer's current responsibilities will be shared by Nicolas Ploquin and Luis Menezes. Ploquin, currently CEO of Unilabs' France will be in charge of part of region south as regional director France, Spain, and Benelux. Menezes, currently CEO of Unilabs Portugal, will also be regional director Portugal, Latin America and the Middle East. 

Christian Rebhan, Unilabs CMO and head of customer excellence, will take over charge of the telemedicine unit from Boehmer and will replace Jacques Herber as head of the operations team. Herber is leaving Unilabs.

Lastly, Martin Schlatter, currently Regional Director Centre, also will become Unilabs' chief commercial officer. 

Oct 15, 2019

Anixa BioSciences: Thomas Schlumpberger

Anixa Biosciences has appointed Thomas Schlumpberger as executive VP, diagnostics. Prior to joining Anixa Schlumpberger held executive roles with several diagnostic companies over the past 20 years, including InVitae, Affymetrix (now Thermo-Fisher Scientific), Inivata, and Singulex. 

Oct 15, 2019

Fluxergy: Ali Tinzali

Fluxergy, an Irvine, California-based developer of point-of-care diagnostics systems, has appointed Ali Tinzali as chief commercial officer. Tinzali joins Fluxergy from Hewlett-Packard, where he led corporate-wide global strategy for healthcare and life sciences. He has also worked in corporate development at Applied Biosystems (now Thermo Fisher Scientific). He also worked for Sony where he helped build a healthcare consumables business that was acquired by Stratec.

Oct 14, 2019

Renalytix AI: Chirag Parikh

AI-based kidney disease diagnostic firm Renalytix AI appointed Chirag Parikh to its board. He is the director of the division of nephrology and the Ronald Peterson professor of medicine at the Johns Hopkins School of Medicine. He has published more than 250 original articles, which have been cited more than 35,000 times. 

Oct 10, 2019

Stilla Technologies: Ruth Szebries

Stilla Technologies has appointed Ruth Szebries as general manager and vice president of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as that firm's senior director for global market development.

Oct 09, 2019

First Light Diagnostics: Angela Caliendo

First Light Diagnostics has added Angela Caliendo to its clinical advisory board. She is an editor at the Journal of Clinical Microbiology, a board member and fellow of the Infectious Diseases Society of America, and a fellow at the American Academy of Microbiology. She currently is a professor and the executive vice chair of the department of medicine at the Warren Alpert Medical School of Brown University. 

Oct 09, 2019

VolitionRx: Phillip Barnes

VolitionRx has appointed Phillip Barnes to its board, replacing Habib Skaff, who resigned effective Oct. 9. Barnes is a British physician and has been a clinician and clinical manager with the UK National Health Service and related academic institutions. 

Oct 08, 2019

Biodesix: James Jett

Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013. 

Oct 04, 2019

Meridian Bioscience: Bryan Baldasare

Meridian has appointed Bryan Baldasare to chief financial officer. He was previously the interim CFO, corporate controller, and treasurer and is currently also the executive vice president and chief accounting officer. Baldasare has been with Meridian since 2000, and before that he was a senior audit manager at Arthur Andersen LLP.